CD38 在临床肿瘤治疗中的作用研究进展。
Research progress in the role of CD38 in clinical tumor treatment.
机构信息
Department of Oncology, Xiangya Hospital, Central South University, Changsha 410008. hezhengxi@ csu.edu.cn.
Cancer Research Institute, Central South University, Changsha 410078. hezhengxi@ csu.edu.cn.
出版信息
Zhong Nan Da Xue Xue Bao Yi Xue Ban. 2022 Jul 28;47(7):952-959. doi: 10.11817/j.issn.1672-7347.2022.210351.
Tumor is one of the ten leading causes of death in the world. Traditional tumor treatments include surgery, radiation therapy, and chemotherapy. With the development of immune checkpoint blockade therapy targeting the programmed death 1/programmed cell death 1 ligand 1 (PD-1/PD-L1) axis, the number of cancers in solid tumors has increased. Changes in the immunometabolic microenvironment have been shown to be important regulators of innate suppression of immune cell function and acquired resistance to immunotherapy. As a new target, CD38 is an enzyme that produces immunosuppressive metabolites (such as adenosine), which can be used in combination with immunotherapy to improve the clinical efficacy of tumor therapy, and can also be used as an indicator for understanding tumor immunotherapy response.
肿瘤是世界十大主要死亡原因之一。传统的肿瘤治疗方法包括手术、放射治疗和化学疗法。随着针对程序性死亡受体 1/程序性死亡配体 1（PD-1/PD-L1）轴的免疫检查点阻断疗法的发展，实体肿瘤中的癌症数量有所增加。免疫代谢微环境的变化已被证明是先天抑制免疫细胞功能和获得性免疫治疗耐药的重要调节剂。CD38 作为一种新的靶点，是一种产生免疫抑制代谢物（如腺苷）的酶，可与免疫疗法联合使用，以提高肿瘤治疗的临床疗效，也可作为了解肿瘤免疫治疗反应的指标。
Zotero 插件